Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
PRVB Stock Summary
In the News
The 5 Best- and Worst-Performing Mid-Cap Stocks in March 2023
March was a good month for the stock market, with the S&P 500 gaining about 3.5%.
Why Provention Bio Stock Skyrocketed 256% This Week
Sanofi plans to acquire Provention Bio for around $2.9 billion. The deal will add Provention's type 1 diabetes drug Tzield to Sanofi's lineup.
Provention (PRVB) Skyrockets 260% on Buyout Offer From Sanofi
Provention Bio (PRVB) to be acquired by pharma-giant Sanofi (SNY) for $2.9 billion. The transaction is likely to close by second-quarter 2023.
This biopharma stock jumped over 250% on Monday: what happened?
Shares of Provention Bio Inc (NASDAQ: PRVB) more than tripled on Monday after Sanofi S.A. (EPA: SAN) confirmed plans of buying the biopharmaceutical company that focused on autoimmune diseases.
Monday Merger Mania Just Made These 2 Biotech Stocks Big Winners
Markets were mixed on a volatile day on Wall Street. Sanofi offered to buy Provention Bio at a price more than triple where the stock closed Friday.
Regional banks pace decliners, as biotech deals lift Seagen and Provention Bio
Here are some of the biggest movers on Monday with banks firmly in focus after federal regulators stepped into protect deposits at fallen bank SVB.
Provention Bio shares soar after Sanofi agrees to buy company in $2.9B cash deal
French drugmaker Sanofi has announced an agreement to acquire US-based biopharmaceutical company Provention Bio Inc (NASDAQ:PRVB), which focuses on autoimmune diseases, for $25 per share in cash, or a total equity value of about $2.9 billion. Provention Bio's stock surged more than 250% in early trading on Monday, while shares of Sanofi slipped 1%.
Why Is Provention Bio (PRVB) Stock Up 263% Today?
Provention Bio (NASDAQ: PRVB ) stock is rocketing higher on Monday following news that Sanofi (NASDAQ: SNY ) is acquiring the company. That deal has Sanofi agreeing to acquire Provention Bio for $25 per share in cash.
Provention Bio Cancels Fourth Quarter and Full Year 2022 Earnings Release and Conference Call
RED BANK, N.J. , March 13, 2023 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced it has cancelled the release of its fourth quarter and full year financial results for the period ended December 31, 2022 due to the announcement earlier today that Provention has entered into a definitive agreement to be acquired by Sanofi, Provention's U.S. TZIELD co-promotion partner, subject to customary regulatory and other closing conditions.
Sanofi To Buy Provention Bio In $2.9 Billion Deal (SNY) (PRVB)
Sanofi (NASDAQ: SNY) announced it is buying Provention Bio (NASDAQ: PRVB) as part of a $2.9 billion deal. These are the details.
PRVB Financial details
PRVB Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0.02 | 0.17 | |
Net income per share | -1.18 | -1.04 | -1.88 | -1.81 | -1.52 | |
Operating cash flow per share | -1.01 | -0.89 | -1.46 | -1.51 | -1.01 | |
Free cash flow per share | -1.01 | -0.89 | -1.48 | -1.53 | -1.02 | |
Cash per share | 2.61 | 2.1 | 2.32 | 1.51 | 2.21 | |
Book value per share | 2.66 | -1.94 | -3.39 | -4.63 | 1.63 | |
Tangible book value per share | 2.66 | -1.94 | -3.39 | 1.75 | 0.83 | |
Share holders equity per share | 2.66 | -1.94 | -3.39 | -4.63 | 1.63 | |
Interest debt per share | 0 | 0 | 0.01 | 0.01 | 0.33 | |
Market cap | 39.72M | 607.13M | 888.62M | 354.63M | 789.82M | |
Enterprise value | -18.82M | 567.97M | 787.04M | 277.03M | 769.69M | |
P/E ratio | -1.5 | -14.39 | -9.01 | -3.1 | -6.95 | |
Price to sales ratio | 0 | 0 | 0 | 254.21 | 61.25 | |
POCF ratio | -1.75 | -16.83 | -11.64 | -3.72 | -10.47 | |
PFCF ratio | -1.75 | -16.83 | -11.47 | -3.68 | -10.36 | |
P/B Ratio | 0.67 | -7.68 | -5 | -1.21 | 6.48 | |
PTB ratio | 0.67 | -7.68 | -5 | -1.21 | 6.48 | |
EV to sales | 0 | 0 | 0 | 198.59 | 59.69 | |
Enterprise value over EBITDA | 0.71 | -12.8 | -7.9 | -2.4 | -6.17 | |
EV to operating cash flow | 0.83 | -15.75 | -10.31 | -2.9 | -10.21 | |
EV to free cash flow | 0.83 | -15.75 | -10.16 | -2.88 | -10.1 | |
Earnings yield | -0.67 | -0.07 | -0.11 | -0.32 | -0.14 | |
Free cash flow yield | -0.57 | -0.06 | -0.09 | -0.27 | -0.1 | |
Debt to equity | 0 | 0 | 0 | 0 | 0.2 | |
Debt to assets | 0 | 0 | 0.01 | 0 | 0.1 | |
Net debt to EBITDA | 2.2 | 0.88 | 1.02 | 0.67 | 0.16 | |
Current ratio | 32.89 | 22.39 | 7.56 | 4.44 | 1.93 | |
Interest coverage | 0 | 0 | 0 | 0 | -123.59 | |
Income quality | 0.86 | 0.83 | 0.77 | 0.83 | 0.66 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 33.94 | 4.97 | |
Research and developement to revenue | 0 | 0 | 0 | 49.91 | 5.88 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0.25 | |
Capex to operating cash flow | 0 | 0 | 0.01 | 0.01 | 0.01 | |
Capex to revenue | 0 | 0 | 0 | -0.69 | -0.06 | |
Capex to depreciation | 0 | 0 | -33.67 | -2.48 | -0.65 | |
Stock based compensation to revenue | 0 | 0 | 0 | 8.49 | 1.48 | |
Graham number | 8.4 | 6.72 | 11.97 | 13.74 | 7.47 | |
ROIC | -0.45 | 0.55 | 0.56 | 0.39 | -0.78 | |
Return on tangible assets | -0.43 | 0.56 | -0.77 | -0.84 | -0.64 | |
Graham Net | 2.53 | 2 | -3.51 | 1.11 | 0.69 | |
Working capital | 59.66M | 82.16M | 109.82M | 78.31M | 84.26M | |
Tangible asset value | 59.66M | -79.06M | -177.64M | 110.73M | 62.29M | |
Net current asset value | 59.66M | 82.16M | -179.61M | 76.21M | 59.64M | |
Invested capital | 0 | 0 | 0 | 0 | 0.2 | |
Average receivables | 0 | 0 | 0 | 0 | 679.5K | |
Average payables | 513.87K | 1.17M | 4.67M | 5.56M | 5.15M | |
Average inventory | 0 | 0 | 0 | 0 | 615.5K | |
Days sales outstanding | 0 | 0 | 0 | 0 | 38.47 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 4.82K | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 877.57 | |
Receivables turnover | 0 | 0 | 0 | 0 | 9.49 | |
Payables turnover | 0 | 0 | 0 | 0 | 0.08 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0.42 | |
ROE | -0.44 | 0.53 | 0.55 | 0.39 | -0.93 | |
Capex per share | 0 | 0 | -0.02 | -0.02 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2022-12-31 for Q4
Metric | History | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.01 | 0.01 | 0.01 | 0.01 | 0.14 | |
Net income per share | -0.41 | -0.35 | -0.46 | -0.34 | -0.45 | |
Operating cash flow per share | -0.37 | -0.24 | -0.44 | -0.29 | -0.11 | |
Free cash flow per share | -0.37 | -0.24 | -0.44 | -0.29 | -0.11 | |
Cash per share | 1.5 | 1.34 | 1.31 | 2.23 | 2.21 | |
Book value per share | 1.75 | 1.49 | 1.22 | 1.74 | 1.63 | |
Tangible book value per share | 1.75 | 1.49 | 1.22 | 1.74 | 0.83 | |
Share holders equity per share | 1.75 | 1.49 | 1.22 | 1.74 | 1.63 | |
Interest debt per share | 0.01 | 0.01 | 0.01 | 0.29 | 0.33 | |
Market cap | 356.17M | 464.09M | 258.86M | 374.04M | 789.82M | |
Enterprise value | 278.57M | 389.73M | 201.5M | 295.43M | 769.69M | |
P/E ratio | -3.45 | -5.28 | -2.19 | -3.32 | -5.93 | |
Price to sales ratio | 496.75 | 800.15 | 347 | 494.76 | 73.04 | |
POCF ratio | -15.18 | -30.88 | -9.1 | -15.61 | -99.04 | |
PFCF ratio | -15.16 | -30.88 | -9.03 | -15.48 | -94.61 | |
P/B Ratio | 3.22 | 4.93 | 3.29 | 2.58 | 6.48 | |
PTB ratio | 3.22 | 4.93 | 3.29 | 2.58 | 6.48 | |
EV to sales | 388.52 | 671.95 | 270.11 | 390.78 | 71.18 | |
Enterprise value over EBITDA | -10.84 | -13.47 | -6.79 | -10.46 | -20.24 | |
EV to operating cash flow | -11.88 | -25.93 | -7.09 | -12.33 | -96.51 | |
EV to free cash flow | -11.85 | -25.93 | -7.03 | -12.23 | -92.2 | |
Earnings yield | -0.07 | -0.05 | -0.11 | -0.08 | -0.04 | |
Free cash flow yield | -0.07 | -0.03 | -0.11 | -0.06 | -0.01 | |
Debt to equity | 0.01 | 0.01 | 0.01 | 0.16 | 0.2 | |
Debt to assets | 0 | 0 | 0 | 0.12 | 0.1 | |
Net debt to EBITDA | 3.02 | 2.57 | 1.93 | 2.78 | 0.53 | |
Current ratio | 4.44 | 3.39 | 3.59 | 7.58 | 1.93 | |
Interest coverage | 0 | 510.19 | -204.34 | -114.03 | -51.37 | |
Income quality | 0.91 | 0.68 | 0.96 | 0.84 | 0.24 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 15.8 | 21.22 | 18.77 | 17.85 | 2.25 | |
Research and developement to revenue | 21.27 | 29.92 | 22.22 | 21.61 | 2.36 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0.25 | |
Capex to operating cash flow | 0 | 0 | 0.01 | 0.01 | 0.05 | |
Capex to revenue | -0.06 | 0 | -0.3 | -0.26 | -0.03 | |
Capex to depreciation | -0.31 | 0 | -1.66 | -1.36 | -0.46 | |
Stock based compensation to revenue | 3.61 | 5.72 | 4.29 | 4.36 | 0.85 | |
Graham number | 4 | 3.4 | 3.53 | 3.65 | 4.04 | |
ROIC | -0.23 | -0.23 | -0.37 | -0.17 | -0.23 | |
Return on tangible assets | -0.19 | -0.18 | -0.28 | -0.15 | -0.19 | |
Graham Net | 1.11 | 0.9 | 0.91 | 1.64 | 0.69 | |
Working capital | 78.31M | 64.74M | 65.15M | 165.32M | 84.26M | |
Tangible asset value | 110.73M | 94.21M | 78.68M | 144.77M | 62.29M | |
Net current asset value | 76.21M | 63.53M | 64.63M | 141.29M | 59.64M | |
Invested capital | 0.01 | 0.01 | 0.01 | 0.16 | 0.2 | |
Average receivables | 0 | 0 | 0 | 0 | 679.5K | |
Average payables | 3.59M | 5.39M | 6.45M | 4.72M | 5.28M | |
Average inventory | 0 | 0 | 0 | 0 | 615.5K | |
Days sales outstanding | 0 | 0 | 0 | 0 | 11.31 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 1.19K | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 216.39 | |
Receivables turnover | 0 | 0 | 0 | 0 | 7.96 | |
Payables turnover | 0 | 0 | 0 | 0 | 0.08 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0.42 | |
ROE | -0.23 | -0.23 | -0.38 | -0.19 | -0.27 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
PRVB Frequently Asked Questions
What is Provention Bio, Inc. stock symbol ?
Provention Bio, Inc. is a US stock , located in Red bank of Nj and trading under the symbol PRVB
What is Provention Bio, Inc. stock quote today ?
Provention Bio, Inc. stock price is $24.98 today.
Is Provention Bio, Inc. stock public?
Yes, Provention Bio, Inc. is a publicly traded company.